Xenon Pharmaceuticals
XENE
118 hedge funds and large institutions have $521M invested in Xenon Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 9 closing their positions.
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
36% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $22.3M
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
15% more funds holding
Funds holding: 103 → 118 (+15)
0.99% more ownership
Funds ownership: 81.94% → 82.93% (+0.99%)
22% less capital invested
Capital invested by funds: $671M → $521M (-$150M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.2M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.84M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$9.82M |
| 4 |
PA
Perceptive Advisors
New York
|
+$5.96M |
| 5 |
TLP
Tri Locum Partners
New York
|
+$4.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$27.7M |
| 2 |
O
OrbiMed
New York
|
-$14.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.08M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$5.94M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.57M |
XENE Hedge Fund Activity: Q3 2021 in Review
118 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2021, worth a combined $521M — down 22% from $671M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new XENE positions and 9 closed out — a net gain of 16 holders — while 35 added to existing stakes and 30 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $12.2M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $27.7M sold.
- 118 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2021, up from 103 in Q2 2021.
- Funds reported $521M of Xenon Pharmaceuticals stock for Q3 2021, down 22% quarter-over-quarter.
- 25 funds opened new Xenon Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +16 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2021 was Great Point Partners, an estimated $12.2M added.
- The largest Xenon Pharmaceuticals seller in Q3 2021 was Eventide Asset Management, an estimated $27.7M sold.
Based on aggregated 13F filings for Q3 2021.